Brentuximab vedotin plus dacarbazine or nivolumab in classical Hodgkin lymphoma; loss of CD20 causes resistance to mosunetuzumab in r/r B-cell lymphomas; trogocytosis as a driver of RBC antigen loss
This Blood Podcast episode covers a trial of brentuximab vedotin in Hodgkin lymphoma, resistance to mosunetuzumab due to CD20 antigen loss in B-cell lymphomas, and the role of trogocytosis in red blood cell antigen loss.